Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol

FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk

(2015) M. Spina et al.   ANNALS OF ONCOLOGY

Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology

(2015) Gail L Jones et al.   BRITISH JOURNAL OF HAEMATOLOGY

Risk of Anaphylaxis with Repeated Courses of Rasburicase: A Research on Adverse Drug Events and Reports (RADAR) Project

(2015) Katherine C. Allen et al.   DRUG SAFETY

Hypouricemic effect and safety of febuxostat used for prevention of tumor lysis syndrome

(2014) Koichiro Maie et al.   SpringerPlus

Rasburicase in Tumor Lysis Syndrome of the Adult: A Systematic Review and Meta-analysis

(2013) Maria A. Lopez-Olivo et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Allopurinol Hypersensitivity: A Systematic Review of All Published Cases, 1950–2012

(2013) Sheena N. Ramasamy et al.   DRUG SAFETY

Generalized multidimensional dynamic allocation method

(2012) Jonathan Lebowitsch et al.   STATISTICS IN MEDICINE

Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus

(2010) Mitchell S. Cairo et al.   BRITISH JOURNAL OF HAEMATOLOGY

Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review

(2008) Bertrand Coiffier et al.   JOURNAL OF CLINICAL ONCOLOGY